Acne Vulgaris - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 170 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acne Vulgaris - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acne Vulgaris - Pipeline Review, H1 2015', provides an overview of the Acne Vulgaris's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acne Vulgaris and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acne Vulgaris pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acne Vulgaris Overview 10
Therapeutics Development 11
Pipeline Products for Acne Vulgaris - Overview 11
Pipeline Products for Acne Vulgaris - Comparative Analysis 12
Acne Vulgaris - Therapeutics under Development by Companies 13
Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes 16
Acne Vulgaris - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Acne Vulgaris - Products under Development by Companies 20
Acne Vulgaris - Products under Investigation by Universities/Institutes 24
Acne Vulgaris - Companies Involved in Therapeutics Development 25
Advancell 25
Allergan, Inc. 26
AndroScience Corporation 27
Biomar Microbial Technologies 28
Braintree Laboratories, Inc. 29
Brickell Biotech, Inc. 30
Celtaxsys, Inc. 31
Cosmo Pharmaceuticals S.p.A 32
Cutanea Life Sciences 33
Delenex Therapeutics AG 34
Deltanoid Pharmaceuticals Inc. 35
Dermira Inc. 36
ELORAC, Inc. 37
Ensoltek Co., Ltd. 38
Foamix Pharmaceuticals Ltd. 39
Galderma S.A. 40
GlaxoSmithKline plc 41
Helix BioMedix, Inc. 42
Hovione FarmaCiencia SA 43
Kasiak Research Pvt. Ltd. 44
Lee's Pharmaceutical Holdings Limited 45
Maruho Co., Ltd. 46
Nabriva Therapeutics AG 47
Novabiotics Ltd 48
Novan, Inc. 49
OrigImm e.U. 50
Paratek Pharmaceuticals, Inc. 51
Phosphagenics Limited 52
Photocure ASA 53
Provectus Biopharmaceuticals, Inc. 54
QLT Inc. 55
RestorGenex Corporation 56
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 57
Telesso Technologies Limited 58
Thesan Pharmaceuticals, Inc. 59
Toyama Chemical Co., Ltd. 60
Valeant Pharmaceuticals International, Inc. 61
Venn Life Sciences Holdings Plc 62
XBiotech USA, Inc. 63
Xenon Pharmaceuticals Inc. 64
Acne Vulgaris - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Target 67
Assessment by Mechanism of Action 69
Assessment by Route of Administration 71
Assessment by Molecule Type 73
Drug Profiles 75
(adapalene + benzoyl peroxide) - Drug Profile 75
(adapalene + clindamycin hydrochloride) - Drug Profile 76
Aczone X - Drug Profile 77
AD-037 - Drug Profile 78
aminolevulinic acid hydrochloride - Drug Profile 79
ANs-29 - Drug Profile 80
ASCJ-9 - Drug Profile 81
BBI-3000 - Drug Profile 83
BC-7013 - Drug Profile 84
becocalcidiol - Drug Profile 85
benzoyl peroxide - Drug Profile 86
benzoyl peroxide - Drug Profile 87
BLI-1100 - Drug Profile 88
BPX-01 - Drug Profile 89
CB-0301 - Drug Profile 90
CB-0604 - Drug Profile 92
CTX-4430 - Drug Profile 93
DLX-2323 - Drug Profile 94
DLX-2681 - Drug Profile 95
DRM-01 - Drug Profile 96
Drugs for Acne - Drug Profile 97
E-10215 - Drug Profile 98
finasteride - Drug Profile 99
GSK-1940029 - Drug Profile 100
HB-1345 - Drug Profile 101
Hesed-4000 - Drug Profile 102
IB-07A037 - Drug Profile 103
IDP-120 - Drug Profile 104
lemuteporfin - Drug Profile 105
methyl aminolevulinate hydrochloride - Drug Profile 106
minocycline - Drug Profile 108
minocycline - Drug Profile 110
MTC-896 - Drug Profile 111
NAI-003 - Drug Profile 113
NVN-1000 - Drug Profile 114
omiganan pentahydrochloride - Drug Profile 115
onabotulinumtoxin A - Drug Profile 117
ozenoxacin - Drug Profile 118
Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile 119
PH-10 - Drug Profile 120
RA-18C3 - Drug Profile 122
Refaglo - Drug Profile 124
RES-440 - Drug Profile 125
sarecycline hydrochloride - Drug Profile 126
Small Molecule for Acne - Drug Profile 128
Small Molecule for Acne and Inflammatory Skin Diseases - Drug Profile 129
SYN-1113 - Drug Profile 131
Synthetic Peptide for Acne Vulgaris - Drug Profile 132
tretinoin - Drug Profile 133
trifarotene - Drug Profile 135
Vaccine for Acne Vulgaris - Drug Profile 136
Vaccine for Acne Vulgaris - Drug Profile 137
XEN-801 - Drug Profile 138
Acne Vulgaris - Recent Pipeline Updates 139
Acne Vulgaris - Dormant Projects 150
Acne Vulgaris - Discontinued Products 157
Acne Vulgaris - Product Development Milestones 158
Featured News & Press Releases 158
Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 166
Disclaimer 167

List of Tables

Number of Products under Development for Acne Vulgaris, H1 2015 14
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Development by Companies, H1 2015 (Contd..3) 26
Products under Investigation by Universities/Institutes, H1 2015 27
Acne Vulgaris - Pipeline by Advancell, H1 2015 28
Acne Vulgaris - Pipeline by Allergan, Inc., H1 2015 29
Acne Vulgaris - Pipeline by AndroScience Corporation, H1 2015 30
Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H1 2015 31
Acne Vulgaris - Pipeline by Braintree Laboratories, Inc., H1 2015 32
Acne Vulgaris - Pipeline by Brickell Biotech, Inc., H1 2015 33
Acne Vulgaris - Pipeline by Celtaxsys, Inc., H1 2015 34
Acne Vulgaris - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 35
Acne Vulgaris - Pipeline by Cutanea Life Sciences, H1 2015 36
Acne Vulgaris - Pipeline by Delenex Therapeutics AG, H1 2015 37
Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015 38
Acne Vulgaris - Pipeline by Dermira Inc., H1 2015 39
Acne Vulgaris - Pipeline by ELORAC, Inc., H1 2015 40
Acne Vulgaris - Pipeline by Ensoltek Co., Ltd., H1 2015 41
Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 42
Acne Vulgaris - Pipeline by Galderma S.A., H1 2015 43
Acne Vulgaris - Pipeline by GlaxoSmithKline plc, H1 2015 44
Acne Vulgaris - Pipeline by Helix BioMedix, Inc., H1 2015 45
Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H1 2015 46
Acne Vulgaris - Pipeline by Kasiak Research Pvt. Ltd., H1 2015 47
Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 48
Acne Vulgaris - Pipeline by Maruho Co., Ltd., H1 2015 49
Acne Vulgaris - Pipeline by Nabriva Therapeutics AG, H1 2015 50
Acne Vulgaris - Pipeline by Novabiotics Ltd, H1 2015 51
Acne Vulgaris - Pipeline by Novan, Inc., H1 2015 52
Acne Vulgaris - Pipeline by OrigImm e.U., H1 2015 53
Acne Vulgaris - Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 54
Acne Vulgaris - Pipeline by Phosphagenics Limited, H1 2015 55
Acne Vulgaris - Pipeline by Photocure ASA, H1 2015 56
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 57
Acne Vulgaris - Pipeline by QLT Inc., H1 2015 58
Acne Vulgaris - Pipeline by RestorGenex Corporation, H1 2015 59
Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 60
Acne Vulgaris - Pipeline by Telesso Technologies Limited, H1 2015 61
Acne Vulgaris - Pipeline by Thesan Pharmaceuticals, Inc., H1 2015 62
Acne Vulgaris - Pipeline by Toyama Chemical Co., Ltd., H1 2015 63
Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 64
Acne Vulgaris - Pipeline by Venn Life Sciences Holdings Plc, H1 2015 65
Acne Vulgaris - Pipeline by XBiotech USA, Inc., H1 2015 66
Acne Vulgaris - Pipeline by Xenon Pharmaceuticals Inc., H1 2015 67
Assessment by Monotherapy Products, H1 2015 68
Assessment by Combination Products, H1 2015 69
Number of Products by Stage and Target, H1 2015 71
Number of Products by Stage and Mechanism of Action, H1 2015 73
Number of Products by Stage and Route of Administration, H1 2015 75
Number of Products by Stage and Molecule Type, H1 2015 77
Acne Vulgaris Therapeutics - Recent Pipeline Updates, H1 2015 142
Acne Vulgaris - Dormant Projects, H1 2015 153
Acne Vulgaris - Dormant Projects (Contd..1), H1 2015 154
Acne Vulgaris - Dormant Projects (Contd..2), H1 2015 155
Acne Vulgaris - Dormant Projects (Contd..3), H1 2015 156
Acne Vulgaris - Dormant Projects (Contd..4), H1 2015 157
Acne Vulgaris - Dormant Projects (Contd..5), H1 2015 158
Acne Vulgaris - Dormant Projects (Contd..6), H1 2015 159
Acne Vulgaris - Discontinued Products, H1 2015 160